Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States?
Glenn E PalomakiEdward R AshwoodRobert G BestGeralyn M Lambert-MesserlianGeorge J KnightPublished in: Genetics in medicine : official journal of the American College of Medical Genetics (2015)
As of 2014, maternal plasma DNA testing appears to have had only a minor impact on serum screening rates in the United States. Ongoing surveillance has the potential to determine if, and when, DNA testing begins to replace serum testing as a primary screen for Down syndrome in the United States.